Connection

Co-Authors

This is a "connection" page, showing publications co-authored by PRAJNAN DAS and CHING-WEI DAVID TZENG.
Connection Strength

0.750
  1. Measurable imaging-based changes in enhancement of intrahepatic cholangiocarcinoma after radiotherapy reflect physical mechanisms of response. medRxiv. 2024 Sep 12.
    View in: PubMed
    Score: 0.061
  2. Escalated-dose radiotherapy for unresected locally advanced pancreatic cancer: Patterns of care and survival in the United States. Cancer Med. 2024 Jun; 13(12):e7434.
    View in: PubMed
    Score: 0.060
  3. Phase I trial of single-photon emission computed tomography-guided liver-directed radiotherapy for patients with low functional liver volume. JNCI Cancer Spectr. 2024 Apr 30; 8(3).
    View in: PubMed
    Score: 0.060
  4. Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial. Lancet Oncol. 2023 12; 24(12):1387-1398.
    View in: PubMed
    Score: 0.058
  5. Brain Metastases from Biliary Tract Cancer: Case Series and Clinicogenomic Analysis. Oncologist. 2023 04 06; 28(4):327-332.
    View in: PubMed
    Score: 0.055
  6. Definitive Liver Radiotherapy for Intrahepatic Cholangiocarcinoma with Extrahepatic Metastases. Liver Cancer. 2023 Aug; 12(3):198-208.
    View in: PubMed
    Score: 0.055
  7. Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase 1 Trial and Imaging-based Biomarker Validation. Int J Radiat Oncol Biol Phys. 2022 11 01; 114(3):444-453.
    View in: PubMed
    Score: 0.053
  8. Ablative liver radiotherapy for unresected intrahepatic cholangiocarcinoma: Patterns of care and survival in the United States. Cancer. 2022 07 01; 128(13):2529-2539.
    View in: PubMed
    Score: 0.052
  9. NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience. Clin Transl Radiat Oncol. 2022 Mar; 33:66-69.
    View in: PubMed
    Score: 0.051
  10. Benchmarking Outcomes after Ablative Radiotherapy for Molecularly Characterized Intrahepatic Cholangiocarcinoma. J Pers Med. 2021 Dec 01; 11(12).
    View in: PubMed
    Score: 0.051
  11. Treatment Patterns for Gastroesophageal Junction Adenocarcinoma in the United States. J Clin Med. 2020 Oct 29; 9(11).
    View in: PubMed
    Score: 0.047
  12. Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma. Cancer Med. 2018 10; 7(10):4880-4892.
    View in: PubMed
    Score: 0.040
  13. Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy. Cancer. 2018 04 15; 124(8):1701-1709.
    View in: PubMed
    Score: 0.039
  14. Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2017 Nov 01; 152(11):1048-1056.
    View in: PubMed
    Score: 0.038
  15. Intraoperative radiation therapy for locally advanced primary and recurrent colorectal cancer: ten-year institutional experience. J Surg Oncol. 2014 Jun; 109(7):652-8.
    View in: PubMed
    Score: 0.029
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.